NCT05597436No Longer Available不适用
An Expanded Access Protocol of Intravenous Trehalose Injection 90.5 mg/mL Treatment of Patients With Amyotrophic Lateral Sclerosis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 21
研究概览
简要总结
This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
详细描述
Approximately 70 participants receive a weekly infusion of SLS-005 for up to 24 weeks. There are 25 infusions over 24 weeks (first infusion occurs at the Screening/Baseline Visit). In addition to infusion visits, participants will have three scheduled in-clinic visits at Screening/Baseline, Week 3, and Week 24, and 2 phone call or telemedicine visits at Week 12 and approximately 28 days following the last dose of the investigational medical product.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sporadic or familial ALS.
- •Age 18 years or older.
- •Cohort 1: Patients who do not qualify for any reasonably accessible ongoing clinical trial.
- •Cohort 2: Patients who have completed the open label extension (OLE) period of Regimen E of the HEALEY ALS Platform Trial and are not eligible for enrollment in another treatment regimen of the platform study.
- •Capable of providing informed consent and complying with study procedures, in the Site Investigator's (SI's) opinion.
- •Participants have established care with a physician at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP.
- •Participants must have a life expectancy of at least 6 months in SI's opinion.
排除标准
- •Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus.
- •Screening glucose >=140 mg/dl.
- •Known hypersensitivity to trehalose.
- •Current use of oral trehalose.
- •Inability for participant to return to site for weekly drug administration, until approved for home infusions.
- •Screening body weight >144 kilograms.
- •Participant with a history of any clinically significant or unstable medical condition or lab abnormality based on the SI's judgment that may interfere with assessment of the study objectives, with safety or full participation.
- •Females who are pregnant or nursing or who plan to get pregnant during the course of the EAP.
- •Females of child-bearing potential, or males, who are unwilling or unable to use highly effective methods of birth control.
- •Use of investigational treatments for ALS (as part of participation in a clinical trial or another EAP) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit.
- •Permanent assisted ventilation (PAV), defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.
- •Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.
- •Presence of unstable psychiatric disease, cognitive impairment, dementia, or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion.
- •Patients who chose to take experimental medications and/or supplements, and that is the only reason they are not eligible for trials, won't be eligible for the EAP.
研究者
研究点 (21)
Loading locations...
相似试验
Available
不适用
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Spinocerebellar AtaxiasSCANCT06034886Biohaven Pharmaceuticals, Inc.
No Longer Available
不适用
Expanded Access to Convalescent Plasma for Treatment of COVID-19COVID-19NCT04472572Hackensack Meridian Health
Approved For Marketing
不适用
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19COVID19NCT04338360Mayo Clinic
Approved For Marketing
不适用
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaCarcinoma, Renal CellNCT00130897Pfizer
No Longer Available
不适用
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 PositiveNon Small Cell Lung Cancer ALK Positive or ROS1 PositiveNCT03178071Pfizer